Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICONS - Early rituximab in childhood-onset nephrotic syndrome
2024-515058-26-00Phase 3Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) comparing Rituximab with Placebo (saline) (2 arms). Primary endpoint: Relapse-free survival during blinded phase. Planned start Nov 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2024-515058-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515058-26-00.